OraSure's Ebola Optionality Meets a Six-Month Slip
Q3 delivered 14% growth and real margin repair, but cash breakeven quietly slid to 2H27 — and the tape has already stopped paying for the story
OSUR · Earnings Call · 2026-11-09
The sentence that mattered was in the guidance section
The headline numbers were genuinely decent. OraSure grew revenue 14% year-over-year to $30.9 million, expanded GAAP gross margin 173 basis points to 45.2%, cut R&D by $1.8 million sequentially and G&A by $2.4 million, and ended with $148.2 million of cash and zero debt. Diagnostics rose 16% on HIV stabilization and Sickle SCAN; Sample Management Solutions rose 21% on commercial customer growth and order timing. On a quarter-to-quarter basis that is the best operating print this company has produced in years.
Then, three-quarters of the way through the prepared remarks, the story changed. Management had spent all of 2026 pointing at cash-flow-from-operations breakeven "entering 2027." Now, as CFO Ken McGrath put it,
as the timing of these opportunities has evolved, we have decided to take a more conservative approach to our estimates, and we now expect to reach cash flow from operations breakeven in the second half of 2027.
That is a half-year of runway conceded, dressed as prudence. The keyword cash flow from operations breakeven still sits in the company's top themes this quarter — but its punch has visibly softened.
This is the central tension of the report: an operating recovery that is real, colliding with a cash timeline that keeps sliding right. And it lands on a stock that had already fallen 22.9% over the prior 90 trading days, from a July 7 peak of $4.32 to roughly $3.33 — a full-drawdown slide into the print rather than a surprise out of it.
Ebola: a catalyst the tape cannot price
What is genuinely new is Ebola. Twelve months ago this was not part of the OraSure vocabulary at all; OraQuick Ebola first surfaced as a ranked theme only in the third quarter of 2026. Now it is the load-bearing beam under the 2027 growth acceleration narrative. The company won FDA emergency use authorization in July for a rapid antigen test covering all four Ebola species, including the Bundibugyo strain driving the current outbreak — more than 10,600 confirmed cases and nearly 5,200 deaths as of November 3, per WHO figures cited on the call.
The problem is the gate. Adoption is expected to run through the BRIDGE Access Study, an independent evaluation led by Africa CDC and WHO with Unitaid support, whose results are meant to inform national registration and procurement. That study was announced in May and dosed in June. It has not yet reported. CEO Carrie Eglinton Manner was unusually candid about that: “quite frankly, I would have expected that already. We are not unusual in waiting for this.” — Carrie Eglinton Manner, President and Chief Executive Officer · 2026-11-09
That admission cuts both ways. It is honest, and it also means the single most important commercial catalyst for 2027 is outside management's control and has already slipped once. There is no global tape confirmation here — no other reporter in this window is talking about Ebola diagnostics, and the market's health-services complex is priced off public health emergency dynamics in insurance and facilities names, not outbreak response. This is a company-idiosyncratic option, and the equity is unlikely to re-rate it until orders are actually booked. The offsetting structural work is real, though: local assembly in Uganda, Nigeria next, and a deepening Africa CDC relationship that shifts the model toward country-led procurement.
What management stopped saying out loud
The most telling keyword move is a subtraction. FDA clearance was among the sharpest decliners in OraSure's own keyword ranking this quarter — and that is not an accident of parsing. The CT/NG Sherlock submission was withdrawn in August; the company is now inside a pre-sub process whose stated purpose is to "align on the best path." On the prior call, Eglinton Manner committed that “we plan to resubmit it... we will update our investors with more on timing as we have that” — Carrie Eglinton Manner · 2026-08-05. Pressed again this quarter, the answer was simply “timing, TBD” — Carrie Eglinton Manner, President and Chief Executive Officer · 2026-11-09.
That matters because CT/NG was the original cash bridge. In August, McGrath argued the delay would be self-funding — “this will not incrementally add to our overall cash flow from operations usage” — Kenneth J. McGrath · 2026-08-05, because milestone payments would be deferred. Deferred milestones are protection, not a plan. With the revenue catalyst pushed out, the company is now leaning on Ebola plus the newly launched Colli-Pee Dx urine collection kit and Sickle SCAN — a plausible but less certain trio. Colli Pee initial sales were called "encouraging"; Sickle SCAN is growing off integration of BioMedomics. Neither is yet large enough to be sized.
The numbers behind the narrative
The growth story is real but must be read against the reset base. Revenue peaked at $120 million in 2023Q2 and has since fallen about 77% to roughly $31 million — the collapse of the COVID testing business. So return to growth is a recovery off a much smaller platform, not a resumption of the old one. Total revenue in the latest reported fundamentals period was $31 million, down 2% year-over-year — the trough quarter just before the Q3 acceleration.
The margin work is the most credible part of the bull case. Gross margin of 43.5% in the June quarter has since improved to 45.2% GAAP in Q3, with management attributing the gain to overhead absorption. And cost discipline is visible in research spend: R&D fell to $9 million in the latest fundamentals period, part of a deliberate taper that McGrath flagged would continue into Q4. But cash is still the tell: free cash flow (less stock comp) was negative $15 million in the latest period, and operating cash flow was negative $10.9 million in Q3.
Which brings us to valuation. Price to revenue sits near 2.7x, versus a 2017 peak above 8x. With a $230 million market cap, $148.2 million of cash and no debt, the enterprise value is roughly $82 million against a guided ~$120 million revenue base. The market is paying almost nothing for Ebola, Colli-Pee, or the Sickle SCAN ramp — it is pricing the burn.
That is the asymmetry worth watching. If Ebola contracting opens before year-end as management expects, and Colli-Pee repeat orders materialize, the breakeven slippage becomes a delay rather than a derailment, and an $82 million enterprise value has real optionality. If the BRIDGE study drifts into 2027 and the cash timeline slips again, this becomes another quarter of "return to growth" rhetoric priced against a balance sheet that is slowly leaking. The next print — and the Q4 call's promised 2027 detail — will decide which.